ENG/中
老虎證券
市场
行情
24/7新闻
产品
Cash Boost账户
期权
A股通
港股
固定票息票据
美股
ETF
基金超市
美国国债
新加坡股
期货
Tiger BOSS Debit Card
老虎钱袋子
功能
经纪人
定投
CPF/SRS 投资
专栏
美股碎股
TigerAI
费用
综合账户
股票与ETF
期权、窝轮与牛熊证
期货
债券
基金超市
Cash Boost
股票与ETF
融资利率
活动
帮助
账户操作
如何开户
开户文件
账户类型
资金与转仓
入金
DDA快捷入金
出金
转入股票
转出股票
货币兑换
产品与交易
可交易产品
订单类型
交易规则
申报
融资融券
保证金与杠杆
风险管理
做空风险
基金超市
基金开户与交易
Cash Boost账户
Cash Boost 账户FAQ
如何开通 Cash Boost 账户
如何用Cash Boost 账户交易
如何绑定CDP证券账户
Tiger Boss Debit Card
常见问题
费用说明
如何充值
如何使用我的Debit card
账单报表
账单报表
股息(分红)
机构
Tiger Fund Management
机构服务
财富及资产管理人
自营交易机构
介绍经纪商
三方服务商
老虎API平台
登入
立即註冊
Toggle
美股
詳情
本頁面由Tiger Trade Technology Pte. Ltd.提供服務
F/m Emerald Life Sciences Innovation ETF
42.61
+0.9321
2.24%
盤後:
42.68
0.0729
+0.17%
16:10 EDT
成交量:
561
成交額:
2.39萬
市值:
1.18億
市盈率:
- -
高:
42.68
開:
42.52
低:
42.52
收:
41.68
52周最高:
48.78
52周最低:
29.44
股本:
277.70萬
流通股本:
277.70萬
量比:
0.36
換手率:
0.02%
股息:
- -
股息率:
- -
淨資產收益率:
--
總資產收益率:
--
市淨率:
--
市盈率(LYR):
- -
資料載入中...
總覽
公司
新聞資訊
公告
博濟醫藥2026年半年報:創新藥研發需求復甦,在手訂單充足,經營現金流明顯下滑
蓝鲸财经
·
08/27
BUZZ——美國股市動態-Semtech、唐納森、Meta
路透中文
·
08/26
Spyre股價下跌,因關節炎藥物未達研發目標
路透中文
·
08/26
Spyre Therapeutics盤前股價重挫12.4% 實驗性藥物未達類風濕關節炎單藥治療開發門檻
美股速递
·
08/26
Spyre Therapeutics公司——療效幅度未達公司預設目標,類風濕關節炎候選藥物SPY072單藥療法開發優先級或將調整
美股速递
·
08/26
Spyre Therapeutics公司:Spy072聯合Il17-a/F治療化膿性汗腺炎(HS)預計於2027年末或2028年初啓動
美股速递
·
08/26
Spyre Therapeutics——Spy072在多項終點指標上較安慰劑展現統計學顯著優勢
美股速递
·
08/26
Spyre Therapeutics公布Spy072 Skyway二期試驗類風濕關節炎亞研究頂線結果
美股速递
·
08/26
美國法院在DNA測序專利糾紛案中裁定Guardant公司支付2.45億美元
路透中文
·
08/24
Twinstrand:法院判決公司及Uw獲賠逾2.452億美元,涵蓋截至2026年5月31日的侵權損害賠償、應計特許權使用費及利息
美股速递
·
08/24
Twinstrand勝訴:法院維持2023年故意侵權判決,並裁定Guardant Health 11項產品與服務須支付6%特許權使用費
美股速递
·
08/24
Twinstrand案判決:Guardant Health須按季度向公司及承銷商彙報11款產品與服務的全美銷售明細
美股速递
·
08/24
Twinstrand:特拉華州法院於8月21日裁定公司及華盛頓大學在針對Guardant Health的專利侵權訴訟中勝訴
美股速递
·
08/24
第3次更新-足球——謝菲爾德聯隊前所有者獲准申請清算當初收購該俱樂部的那家公司
路透中文
·
08/19
中國銀河證券:實驗動物為創新藥研發剛需 小鼠+猴雙主線高景氣
智通财经
·
08/14
美銀證券:中國CXO行業受惠生物科技融資強勁 上調藥明康德等目標價
新浪港股
·
08/13
百花醫藥股價嚴重異常波動:主營小分子化學仿製藥CRO業務 不涉及創新藥研發
央广财经
·
08/12
百花醫藥(600721.SH):不涉及創新藥研發
智通财经
·
08/11
百花醫藥(600721.SH):不涉及創新藥研發
智通财经
·
08/11
東方證券:AI重構創新藥研發底座 國內相關產業鏈公司亦有望受益
智通财经
·
08/11
更多
{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/stock/LFSC/news?page=2"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LFSC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LFSC\",,,,,undefined,":{"symbol":"LFSC","market":"US","secType":"STK","nameCN":"F/m Emerald Life Sciences Innovation ETF","latestPrice":42.6071,"timestamp":1791576000000,"preClose":41.675,"halted":0,"volume":561,"hourTrading":{"tag":"盘后","latestPrice":42.68,"preClose":42.6071,"latestTime":"16:10 EDT","volume":1,"amount":42.6071,"timestamp":1791576604081,"change":0.0729,"changeRate":0.001711,"amplitude":0},"delay":0,"changeRate":0.022365926814637206,"floatShares":2777035,"shares":2777035,"eps":0,"marketStatus":"休市中","change":0.9321,"latestTime":"10-09 16:00:00 EDT","open":42.515,"high":42.68,"low":42.515,"amount":23883,"amplitude":0.003959,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1791792000000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":41.675,"sharesOutstanding":2657035,"nav":41.68,"aum":115746818.8,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":42.68,"preClose":42.6071,"latestTime":"16:10 EDT","volume":1,"amount":42.6071,"timestamp":1791576604081,"change":0.0729,"changeRate":0.001711,"amplitude":0},"volumeRatio":0.35855808645794174},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LFSC\",,,,,undefined,":{"symbol":"LFSC","floatShares":2777035,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.35855808645794174,"shares":2777035,"dividePrice":0,"high":42.68,"amplitude":0.003959,"preClose":41.675,"low":42.515,"week52Low":29.4441,"pbRate":"--","week52High":48.78,"institutionHeld":0,"latestPrice":42.6071,"eps":0,"divideRate":0,"volume":561,"delay":0,"ttmEps":0,"open":42.515,"prevYearClose":36.6147,"prevWeekClose":43.401,"prevMonthClose":44.5697,"prevQuarterClose":44.5697,"fiveDayClose":43.401,"twentyDayClose":45.3275,"sixtyDayClose":44.9054},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LFSC\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LFSC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LFSC\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LFSC\",pageSize:20,pageCount:2,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2662752987","title":"博濟醫藥2026年半年報:創新藥研發需求復甦,在手訂單充足,經營現金流明顯下滑","url":"https://stock-news.laohu8.com/highlight/detail?id=2662752987","media":"蓝鲸财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662752987?lang=zh_tw&edition=fundamental","pubTime":"2026-08-27 14:57","pubTimestamp":1787813849,"startTime":"0","endTime":"0","summary":"然而,需警惕新药研发政策变化、项目执行延期及市场竞争加剧带来的风险,同时关注经营现金流与净利润背离的情况。后续需重点关注公司在手订单转化进度、临床前及临床研究服务的毛利率变化趋势,以及经营现金流的改善情况。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1787797151251328663","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["WRND","BIOY","SBIO","BK0216","BBP","IBB","BK4588","GSKH","GDOC","PBE","SPHQ","LFSC","XLVI","159399","APXH","300404","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662571159","title":"BUZZ——美國股市動態-Semtech、唐納森、Meta","url":"https://stock-news.laohu8.com/highlight/detail?id=2662571159","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662571159?lang=zh_tw&edition=fundamental","pubTime":"2026-08-26 20:32","pubTimestamp":1787747524,"startTime":"0","endTime":"0","summary":"BUZZ——美国股市动态-Semtech、唐纳森、Meta工作区中用于查询单只股票行情的搜索字符串:STXBZ《今日展望》通讯:https://refini.tv/3LI4BU7《晨间新闻简报》:https://refini.tv/3dKUyB8路透8月26日-周三,美国股指期货基本持平,因投资者在人工智能龙头企业Nvidia(辉达/英伟达)公布财报以及可能影响利率预期的备受关注的通胀报告发布前保","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nL4S44N0Y5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4549","LU0225283273.USD","IE00BFSS8Q28.SGD","AIFD","IE00BKVL7J92.USD","LU2065169927.USD","BK4538","LU0109391861.USD","SG9999014898.SGD","SG9999004303.SGD","LU2047632596.USD","LU0122379950.USD","SOXY","LU1914381329.SGD","IE00BZ9MQY76.HKD","LU0823417653.USD","LU2168564495.EUR","IE00B775H168.HKD","LU1496350502.SGD","LU2360032135.SGD","LU0006306889.USD","LU0353189763.USD","LU0354030511.USD","NVD","LU1244550494.USD","LU0426417589.USD","LU1035775433.USD","IE00BJT1NW94.SGD","LU0251132253.USD","LU0053666078.USD","IE00B19Z9P08.USD","ADBG","IE000Q6AESB8.SGD","LU0274383776.USD","LU2506952097.USD","LU0552385451.USD","LU2552382132.HKD","NVDO","LU1116320737.USD","NVII","BHVN","LU1046421795.USD","EYES","LU0203202063.USD","LU0289739343.SGD","LU0889566641.SGD","LU1720051017.SGD","LU2462591277.SGD","LU2125154935.USD","IE00BKDWB100.SGD","LU0823417737.USD","07388","GB00B4LPDJ14.GBP","LU0266013472.USD","LU1066051811.HKD","LU1974910355.USD","LU0795875086.SGD","SHOC","LU0823416689.USD","VOX","IE00B4JS1V06.HKD","LU2362541513.USD","LU2362541273.HKD","IE00BD6J9T35.USD","LU1935042488.USD","LU2097344431.USD","LU2491050154.USD","LU0143551892.USD","IE00B19Z3B42.SGD","LU1983299246.USD","LTL","LU2505996681.GBP","LU1564329032.USD","LU0719512351.SGD","VT","NVC","LU1496350171.SGD","FCOM","LU0048584097.USD","LU0054578231.USD","LU0323591593.USD","ZM","LU1778281490.HKD","LU0154236417.USD","LU1400636657.SGD","PLTU","IE00BK4W5L77.USD","PLTA","LU2028103732.USD","LU1551013425.SGD","LU2290526834.HKD","IE00BQXX3F31.USD","IE00BK4W5M84.HKD","SNVD.UK","LU2264538146.SGD","LU2361044865.SGD","LU0965509283.SGD","LU2430703178.SGD","LU0096364046.USD","NVDS","LU0472753341.HKD","LU1934455277.USD","LU0648000940.SGD","LU1989772840.SGD","LU1670756490.USD","GB00B4QBRK32.GBP","LU1642822529.SGD","SG9999014906.USD","LU0308772762.SGD","IE000F7OJYX1.SGD","METV","LU1242518931.SGD","LU2750360997.AUD","METW","LU2077746001.SGD","IE0034235303.USD","HK0000306685.HKD","BK4077","LU1935043023.USD","LU2236285917.USD","PLTI","LU0072462426.USD","LU0158827948.USD","LU0210528500.USD","LU0238689110.USD","NVD3.UK","ROM","LU0096362180.USD","LU2505996509.AUD","BK4567","LU1823568750.SGD","ABFL","LU1202635105.USD","LU0942090050.USD","SG9999015986.USD","LU0158827781.USD","BK4561","BK4527","HK0000320223.HKD","LU0784385840.USD","LU0784385170.HKD","LU2125909916.SGD","LU0553294199.USD","LU1043141396.HKD","LU2931357623.SGD","LU0345774631.USD","LU2125154778.USD","THMR","IE00BDCRKT87.USD","LU2237443382.USD","LU2462591350.SGD","LU0138981039.USD","LU0784383803.USD","LU0985320562.USD","LU2471134879.HKD","SG9999017495.SGD","GUNZ","NVDD","LU0070302665.USD","LU2092627202.USD","IE00B2B36J28.USD","LU0823434583.USD","LU0823421416.USD","LU0823414478.USD","LU2089283258.USD","LU2347655073.USD","LU0211327993.USD","NOWL","LU0203345920.USD","LU2471134952.CNY","LU0708994859.HKD","LU2065171311.SGD","SPLTRmain","LU2506951958.HKD","LU2750360641.GBP","LU1791710582.SGD","LU0820561818.USD","SG9999018865.SGD","LU0267386448.USD","PLT","BK4547","TTXU","LU1066053197.SGD","LU0048573561.USD","LU0079474960.USD","LU2746668461.USD","LU2756315318.SGD","LU2087625088.SGD","CHAT","HK0000819398.USD","BK4139","LU2087621335.USD","PLTY","LU2462157665.USD","LU1934455863.HKD","IE00B894F039.SGD","LU2063271972.USD","LU1489326972.SGD","NVDL","ADBU","USXF","SOXQ","SMTC","BK4141","BK4581","LU1791710400.SGD","LU2242649171.HKD","IE00BHPRN162.USD","IE00B19Z9505.USD","LU0494093205.USD","LU1992135399.USD","LU1323610961.USD","LU0011850046.USD","LU1145028129.USD","BK4529","IE0009G5SDU7.USD","LU0097036916.USD","LU2433249047.HKD","LU1037948541.HKD","BK4161","LU2552382058.USD","LU2023250504.SGD","LU0788109477.HKD","LU1852331112.SGD","SGXZ80539844.SGD","FBYY","NVDB","LU1153585028.USD","2NVD.UK","GAMR","LU0689472784.USD","LU2054465674.USD","LU0949170772.SGD","LU1880398554.USD","XLC","IE00B19Z9Z06.USD","LU2322448957.HKD","BK4107","LU0162691827.USD","IE00B3S45H60.SGD","LU0444973449.USD","LU1059921491.USD","LU1064131342.USD","LU2430703251.USD","IE00BJJMRY28.SGD","NOWX","LU2543165471.USD","LU1232071149.USD","LU1571399168.USD","IE000ITXATA3.USD","IE00BJTD4V19.USD","IE00BYQQ9H92.USD","LU1670711040.USD","LU0690374615.EUR","ARTY","LU0889565833.HKD","LU2756315664.SGD","NVDU","LU1061106388.HKD","BK4605","LU1868836914.USD","IE000W1ABFV2.USD","LU1804176565.USD","LU2360106780.USD","IE0009356076.USD","LU1951200564.SGD","LU2458330169.SGD","LU2381873111.SGD","LU1720051108.HKD","IE00BQXX3D17.EUR","LU3102509885.SGD","BK4097","LU0882574139.USD","LU2361044949.HKD","LU2458330243.SGD","XDAT","SGXZ99366536.SGD","LU2326559502.SGD","SMETAmain","LU2294711713.HKD","CRMG","LU1951198990.SGD","LU0980610538.SGD","BK4528","LU1880398471.USD","IXN","LU2506951792.HKD","LU2106854487.HKD","LU0965508806.USD","BK4579","LU2860962120.EUR","BK4525","NVDY","IE00BJJMRX11.SGD","META","LU0069063385.USD","LU0124676726.USD","LU0320765059.SGD","LU2065170008.USD","IE0004445015.USD","LU0444971666.USD","PLTD","BK4548","BK4543","LU1861127337.USD","TRUP","LU2764262908.HKD","LU1868836757.USD","LU1691799644.USD","ESLG","SGXZ81514606.USD","LU0861579265.USD","LU0289961442.SGD","RSPC","IE0000B7K699.USD","LU0157215616.USD","LU0081259029.USD","LU0068578508.USD","HK0000914686.HKD","LU0310800965.SGD","LU0466842654.USD","LU1712237335.SGD","LU2133065610.SGD","LU2357125470.USD","LU0114720955.EUR","LU1037948897.HKD","LU2213496289.HKD","LU2491049909.HKD","SG9999002232.USD","NOW","LU1935042215.USD","SGXZ51526630.SGD","LU0251142724.SGD","SG9999002224.SGD","LU0061475181.USD","FDTX","LU1035773651.USD","LU1144417596.USD","IE00B5TLWC47.USD","LU2237443465.HKD","LU1057294990.SGD","LU0130103400.USD","LU1366333091.USD","LU1236620750.USD","LU0215105999.USD","NULC","LU0133085943.USD","BK4504","LU1670627923.USD","LU2108987350.USD","LU0557290698.USD","LU0323240290.USD","LU0878866978.SGD","SG9999015945.SGD","TTEQ","LU2279689827.SGD","3NVD.UK","SGXZ57979304.SGD","LU2125909247.SGD","SG9999014914.USD","LU2237957902.USD","LU1564329628.SGD","EFIV","TRUC","LU0690374961.EUR","LU0127658192.USD","LU0390134368.USD","LU0683600562.USD","METD","SG9999015952.SGD","NVIW.SI","LU1023059063.AUD","NVDQ","SNPE","LU2552382215.SGD","IE00BJTD4N35.SGD","IE0001KFT4U8.USD","BK4587","USD","LU1721428933.USD","LU2125909759.SGD","LU1066051498.USD","LU0545039389.USD","SG9999015341.SGD","LU0316494557.USD","IE00BN29S564.USD","LU2211815571.USD","LU1935043536.SGD","LU0061474705.USD","LU0726765562.USD","LU2506952170.USD","LU0128525689.USD","PLTZ","FAI","IE000YTNTUN2.SGD","LU0528227936.USD","SG9999014567.USD","LU2125909593.SGD","LU0094547139.USD","LU1989764664.SGD","LU1935042991.SGD","LU2413666699.HKD","SMHX","LU0130518102.USD","IE00B3M56506.USD","LU1400636574.HKD","LU0792757196.USD","DCI","LU1670628061.USD","BK4507","LU1861559042.SGD","BK4585","LU0738911758.USD","NVDX","SMTG","LU0345774391.USD","SG9999000418.SGD","ANV","LU1366192091.USD","LU1235294995.USD","LU2286300806.USD","SG9999014559.SGD","SG9999015358.SGD","SGXZ31699556.SGD","SOCL","OGIG","LU1267930227.SGD","LU2083900584.USD","LU1119994496.HKD","PLTW","LU2637965513.SGD","IE00BJLML261.HKD","SG9999001176.USD","LU2602419157.SGD","IE00B775SV38.USD","LU0347712357.USD","LU0912757837.SGD","LU1291159041.SGD","LU2111349929.HKD","SOXX","BK4612","LU0985489474.SGD","LU2404859741.USD","LU1121112475.USD","LU0964807845.USD","LU0417517546.SGD","LU0648001328.SGD","LU2100268510.USD","LU0689626769.HKD","LU0310800379.SGD","GXPC","IE00BQXX3C00.GBP","LU0345770308.USD","LU2089985449.USD","LU0056508442.USD","LU0130517989.USD","IE00BFXG0V08.USD","SG9999001077.SGD","WISE","LU0823421333.USD","LU2403377893.USD","IE000BZT7R73.USD","LU1093756325.SGD","BK4533","LU1803068979.SGD","LU0072461881.USD","LU2394011477.USD","BK4200","IGV","IE00BKPKM429.USD","XLK","LU0211331839.USD","IE00B4YYXB79.USD","SG9999014542.SGD","LU2237957811.SGD","LU0106261372.USD","LU0210533765.USD","LU0130102774.USD","BK4554","IE00B5949003.HKD","LU1645745479.HKD","LU0949170426.SGD","LU2404859667.USD","LU2954938101.SGD","SG9999001176.SGD","LU1992135472.HKD","IE000MB6IJN5.SGD","IE00BFTCPJ56.SGD","LU2097344357.USD","LU0234570918.USD","TEK","LU2452424414.USD","LU0395794307.EUR","AIPI","LU2361045086.USD","NVDA","LU1043141123.HKD","IE0005OL40V9.USD","LU1839511570.USD","IE00BMPRXQ63.HKD","CRM","IE00B19Z8X17.USD","LU0265550359.USD","LU2324357040.USD","LU2112291526.USD","LU2461242641.AUD","LU2463028550.USD","NVDS.UK","LU0057025933.USD","IE0004091025.USD","IE000SO60NU8.SGD","LU0077335932.USD","LU1074936037.SGD","HK0000532082.HKD","IE00BZ199S13.USD","SYRE","NVDG","BK4524","LU0310799852.SGD","LU1629891620.HKD","FBL","LU2244417387.USD","LU0433182093.SGD","LU0795875169.SGD","LU0320765489.SGD","LU1564329461.SGD","LU1923622291.USD","HK0000304797.USD","LU0882574055.USD","LU0868494708.USD","LU2237443622.USD","IE00B19Z3581.USD","BK4505","LU0820562030.AUD","LU0345768153.USD","LU1861220033.SGD","LU1988902786.USD","LU1435385759.SGD","METQ","LU0109392836.USD","LU1429558221.USD","CNEQ","LU0276348264.USD","LU2168564222.USD","LU2362540622.SGD","LU0082616367.USD","LU0174119429.USD","LU1821325948.USD","PTIR","LU0354030438.USD","BK4162","LU0203347892.USD","SNVDAmain","LU1267930813.SGD","LU0979878070.USD","LU1989771016.USD","LU2272731600.USD","BK4082","LU2247934214.USD","LU2095319765.USD","SG9999014575.USD","SG9999015978.USD","DIPS","LU0820561909.HKD","TYLG","LU1267930730.SGD","LU2097829019.USD","LU2347655156.SGD","LU2210150020.SGD","LU0314104364.USD","LU0345768740.USD","IE00BJJMRZ35.SGD","LU0170899867.USD","LU1718418525.SGD","LU0198837287.USD","LU2168564149.EUR","LU2360107168.USD","IE0034235295.USD","IE00B19Z8W00.USD","LU0210536198.USD","LU1201861165.SGD","IE00BWXC8680.SGD","LU2089284900.SGD","PLTL","LU1564329115.USD","NVDW","SPTE","LU2357305700.SGD","LU1989764748.USD","LU1244550221.USD","CMAG","LU2191332357.HKD","IE0009355771.USD","07788","LU0256863902.USD","LU0070217475.USD","HK0000914660.USD","LU0640476718.USD","LU1814569148.SGD","LU2168563687.JPY","LU2249611893.SGD","LU1236620834.HKD","LU2023251221.USD","LU2271345857.HKD","PLOO","LU2242650005.HKD","LU0353189680.USD","LU0823434740.USD","LU2065171402.SGD","LU0029864427.USD","LU1066051225.USD","BBWI","LU0477156953.USD","BK4607","IE00B3SWFQ91.USD","LU0187121727.USD","HK0000320264.USD","LU0724617625.USD","SG9999013999.USD","LU0205193047.USD","IE00BFSS7M15.SGD","LU0950375773.USD","METU","BK4503","INTU","IE0034235188.USD","LU1868836591.USD","LU2168564065.EUR","LU0205194284.USD","LU1979441026.SGD","LU1674673691.USD","LU1917777945.USD","IE0003U64NQ7.SGD","LU1815336760.USD","BK4532","LFGY","LU2023250843.SGD","IE00B4R5TH58.HKD","LU1201861249.SGD","LFSC","SMH","ILDR","LU0256863811.USD","LU0342679015.USD","LU2506951875.HKD","SG9999018857.SGD","LU1548497426.USD","LU1400636491.USD","LU2592432038.USD","LU1301847155.USD","LU2430703095.HKD","LU2272731865.HKD","ESUM","CLOD","VGT","CHPX","LU2896262040.SGD","LU2322448791.USD","LU2764263203.CNY","SG9999001424.SGD","IE0002270589.USD","LU2746668974.SGD","PLTR","LU2023250330.USD","FTEC","LU0476273544.USD","LU2413666426.HKD","LU0203201768.USD","PLTG","LU1732799900.SGD","LU2764263039.SGD","LU0289960550.SGD","LU2456880835.USD","LU0345769631.USD","LU1983260115.SGD","LU1084165304.USD","LU1868837136.USD","LU2720916845.USD","LU1551013342.USD","FBY","LU0128525929.USD","LU0106261612.USD","IE00BZ1G4Q59.USD","BK4551","LU0265550946.USD","LU0787776722.HKD","LU1069347547.HKD","LU1941712348.USD","PLYY","IE0004445239.USD","IE00BDRTCR15.USD","LU2272731782.SGD","LU0107464264.USD","LU1815333072.USD","LU2237443978.SGD","HK0000306701.USD","LU0823414551.USD","LU1732800096.USD","LU2999663052.SGD","BK4592","LU0061474960.USD","LU1116320901.HKD","LU1861558580.USD","SGXZ23171101.USD","LU0251131958.USD","BK4598","LU2210149790.SGD","LU0642271901.SGD","SHLD","LU0323239441.USD","LU1069344957.HKD","LU0080751232.USD","LU1242518857.USD","LU0943347566.SGD","BK4566","BK4550","LU2420271590.USD","LU0012050646.USD","LU1861215975.USD","LU1316542783.SGD","LU0957791311.USD","LU2237438978.USD","LU0511384066.AUD","LU1934455194.USD","BK4614","BK4534","FBX","BK4588","LU0149725797.USD","LU1127390331.HKD","METG","LU0477156797.USD","LU2148611432.USD","NVYY","IE000KEQY171.SGD","LU0957808578.USD","LU1670710661.SGD","LU0175139822.USD","LU0345770993.USD","IETC","LU0211328371.USD","IE00B7KXQ091.USD","LU0672654240.SGD","LU0965509101.SGD","LU0786609619.USD","LU0661504455.SGD","IE00B1BXHZ80.USD","LU1280957306.USD","LU2250418816.HKD","LU1633808545.USD","LU0345769128.USD","LU1093756168.USD","JGRO","LU1267930573.SGD","BK4613","BSX","TRFK","IE000WAW04H5.SGD","LU1261432733.SGD","LU0868494617.USD","LU0234572021.USD","LU1699723380.USD","NVD2.UK","ADBE","LU0965509010.AUD","LU1003077747.HKD","LU2237443549.SGD","LU2471134523.USD","LU0784384876.USD","LU0426412945.USD","LU1989772923.USD","IE00BMPRXN33.USD","LU2317271919.USD","LU0994945656.USD","LU0052756011.USD","LU2092937148.SGD","IE0002141913.USD","SG9999014880.SGD","LU2471134796.USD","LU2417539215.USD","LU1670710588.SGD","IE00B7SZLL34.SGD","LU0208291251.USD","BK4023","LU2491050071.SGD","IE00B1XK9C88.USD","LU1670711123.USD","IE0004086264.USD","LU1923622614.USD","LU1244550577.SGD","HK0000304805.HKD","LU1697837992.HKD","CLSE","LU1923623000.USD","LU2473716301.USD","GB00BDT5M118.USD","AGOX","LU2237443895.HKD","LU0742534661.SGD","LU1941712264.USD","IE00BYXW3230.USD","LU1267930490.SGD","LU2265009873.SGD","LU2487616109.SGD","LU0708995401.HKD","LU0432979614.USD","LU1623119135.USD","LU1868837300.USD","LU0348723411.USD","BK4608","IE00BMPRXR70.SGD","BK4535","LU1674673428.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662791203","title":"Spyre股價下跌,因關節炎藥物未達研發目標","url":"https://stock-news.laohu8.com/highlight/detail?id=2662791203","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662791203?lang=zh_tw&edition=fundamental","pubTime":"2026-08-26 17:29","pubTimestamp":1787736543,"startTime":"0","endTime":"0","summary":"BUZZ-Spyre股价下跌,因关节炎药物未达研发目标8月26日-** 药物研发公司Spyre Therapeutics(SYRE.O)的股价在盘前交易中下跌11.35%,报95.17美元** Spyre的试验性药物SPY072在中期临床试验中改善了类风湿性关节炎的症状(link),但其疗效未达到将其开发为该病单药治疗方案的内部目标** 该研究针对中重度类风湿性关节炎患者(其病情对先前治疗反应不佳","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nL4T44N0LV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYRE","BK4139","LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103784641","title":"Spyre Therapeutics盤前股價重挫12.4% 實驗性藥物未達類風濕關節炎單藥治療開發門檻","url":"https://stock-news.laohu8.com/highlight/detail?id=1103784641","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1103784641?lang=zh_tw&edition=fundamental","pubTime":"2026-08-26 17:00","pubTimestamp":1787734809,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics股价在盘前交易时段大幅下跌12.4%,此前该公司宣布其一款实验性药物未能达到类风湿关节炎单药治疗开发所需的疗效阈值。这一消息令市场投资者颇感意外,引发对该生物科技公司研发管线前景的重新评估。受此利空冲击,该股在常规交易开始前即遭遇显著抛售压力,反映出市场对候选药物临床价值的疑虑正在加深。分析人士指出,未能跨越预设的疗效门槛意味着该药物作为单一疗法的开发路径将面临重大调整,公司或需重新考量其战略布局。投资者正密切关注公司后续的研发决策及可能的替代方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYRE","LFSC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158063890","title":"Spyre Therapeutics公司——療效幅度未達公司預設目標,類風濕關節炎候選藥物SPY072單藥療法開發優先級或將調整","url":"https://stock-news.laohu8.com/highlight/detail?id=1158063890","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1158063890?lang=zh_tw&edition=fundamental","pubTime":"2026-08-26 04:02","pubTimestamp":1787688131,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics公司近日披露,其类风湿关节炎在研药物SPY072在临床试验中展现的疗效幅度未能达到公司预先设定的目标阈值。这一结果意味着,该公司此前规划的单药疗法开发路径——即将SPY072作为独立治疗方案推进的优先策略——如今面临重新审视与调整的现实压力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LFSC","SYRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107207144","title":"Spyre Therapeutics公司:Spy072聯合Il17-a/F治療化膿性汗腺炎(HS)預計於2027年末或2028年初啓動","url":"https://stock-news.laohu8.com/highlight/detail?id=1107207144","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1107207144?lang=zh_tw&edition=fundamental","pubTime":"2026-08-26 04:02","pubTimestamp":1787688130,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics Inc宣布,其候选药物Spy072与Il17-a/F联合疗法用于治疗化脓性汗腺炎(HS)的计划,预计将在2027年末或2028年初推进。这一时间表标志着该公司在炎症性疾病领域管线布局的重要节点,也反映出其对该联合方案临床开发节奏的审慎把控。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LFSC","BK4139","SYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157101849","title":"Spyre Therapeutics——Spy072在多項終點指標上較安慰劑展現統計學顯著優勢","url":"https://stock-news.laohu8.com/highlight/detail?id=1157101849","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1157101849?lang=zh_tw&edition=fundamental","pubTime":"2026-08-26 04:02","pubTimestamp":1787688129,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics宣布,其候选药物Spy072在多项临床试验终点上,相较于安慰剂组,取得了具有统计学意义的显著改善。这一积极结果标志着该药物在治疗潜力上迈出了坚实一步,为后续研发注入了强劲动力。尽管具体数据细节尚未完全披露,但公司方面对Spy072的前景表达了高度信心,并计划加速推进其临床开发进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LFSC","BK4139","SYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103864507","title":"Spyre Therapeutics公布Spy072 Skyway二期試驗類風濕關節炎亞研究頂線結果","url":"https://stock-news.laohu8.com/highlight/detail?id=1103864507","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1103864507?lang=zh_tw&edition=fundamental","pubTime":"2026-08-26 04:02","pubTimestamp":1787688128,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics今日宣布,其Spy072在Skyway二期试验中针对类风湿关节炎亚研究的顶线结果已正式揭晓。这一里程碑式的数据发布,为该公司在自身免疫性疾病领域的研发管线注入了新的看点。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LFSC","BK4139","SYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661227372","title":"美國法院在DNA測序專利糾紛案中裁定Guardant公司支付2.45億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2661227372","media":"路透中文","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661227372?lang=zh_tw&edition=fundamental","pubTime":"2026-08-24 19:21","pubTimestamp":1787570491,"startTime":"0","endTime":"0","summary":"美国法院在DNA测序专利纠纷案中裁定Guardant公司支付2.45亿美元路透8月24日-TwinStrand Biosciences周一表示,美国一家法院裁定Guardant Health公司侵犯了涉及DNA测序技术的专利,并责令其向TwinStrand Biosciences和华盛顿大学支付超过2.452亿美元的赔偿金。法院裁定,Guardant必须就其11项被认定侵犯专利的产品及服务在美国的销售额,支付6%的专利使用费,直至2033年3月相关专利到期为止。TwinStrand表示,该判决所涵盖的产品和服务约占Guardant在侵权期间总收入的90%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nL4T44L0SL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LFSC","FFOX","BK4588","BK4551","BK4196","EKG","GNOM","LU0889565916.HKD","LU0109394709.USD","GH","BK4585","GNMX","BK4535","HELX","LU0320765992.SGD","GDOC","PTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160211496","title":"Twinstrand:法院判決公司及Uw獲賠逾2.452億美元,涵蓋截至2026年5月31日的侵權損害賠償、應計特許權使用費及利息","url":"https://stock-news.laohu8.com/highlight/detail?id=1160211496","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1160211496?lang=zh_tw&edition=fundamental","pubTime":"2026-08-24 19:01","pubTimestamp":1787569302,"startTime":"0","endTime":"0","summary":"Twinstrand公告,法院已作出裁决,判令公司及Uw获得超过2.452亿美元的赔偿金。这笔款项涵盖了截至2026年5月31日期间所发生的侵权损害、累积的特许权使用费以及相应利息。\n裁决金额之巨,彰显了司法体系对知识产权保护的坚定立场。赔偿总额精确计算至该截止日期,包括了多层次的补偿要素。侵权行为的认定范围,则明确划定在2026年5月31日之前发生的全部相关行为。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GNOM","FFOX","LU0889565916.HKD","LU0320765992.SGD","GNMX","PTH","GH","BK4196","EKG","BK4551","BK4535","LU0109394709.USD","GDOC","BK4588","HELX","BK4585","LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194764905","title":"Twinstrand勝訴:法院維持2023年故意侵權判決,並裁定Guardant Health 11項產品與服務須支付6%特許權使用費","url":"https://stock-news.laohu8.com/highlight/detail?id=1194764905","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1194764905?lang=zh_tw&edition=fundamental","pubTime":"2026-08-24 19:01","pubTimestamp":1787569276,"startTime":"0","endTime":"0","summary":"法院裁定,维持2023年关于故意侵权的判决,同时要求Guardant Health公司就其11项产品及服务所产生的销售额,向Twinstrand支付6%的特许权使用费。这一裁决意味着,Twinstrand在知识产权纠纷中取得了关键性胜利。对于Guardant Health而言,这项决定无疑构成了财务上的重大负担。Twinstrand方面则对这一结果表示认可。此次6%特许权使用费的设定,亦反映了法院对此类行为的态度。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","BK4585","BK4551","BK4196","LU0889565916.HKD","BK4588","GH","LU0320765992.SGD","GNOM","BK4535","EKG","FFOX","HELX","PTH","LFSC","GDOC","GNMX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127912643","title":"Twinstrand案判決:Guardant Health須按季度向公司及承銷商彙報11款產品與服務的全美銷售明細","url":"https://stock-news.laohu8.com/highlight/detail?id=1127912643","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1127912643?lang=zh_tw&edition=fundamental","pubTime":"2026-08-24 19:00","pubTimestamp":1787569211,"startTime":"0","endTime":"0","summary":"根据Twinstrand方面的消息,法院判决要求Guardant Health必须履行一项新的义务——按季度提交其在美国市场上全部11款产品与服务的销售账目,以供公司与承销商查阅。\n这一判决意味着,Guardant Health在运营透明度和合规性上将面临更为严格的监督。具体而言,公司需定期整理并呈报相关销售数据,确保各方能够及时掌握其业务动态。\n此举无疑为市场参与者提供了更清晰的视角,去审视这家精准医疗领域领军企业的真实业绩表现。季度汇报机制的建立,或将进一步影响投资者对该公司未来走势的评估与判断。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LFSC","FFOX","BK4588","BK4551","BK4196","EKG","GNOM","LU0889565916.HKD","LU0109394709.USD","GH","BK4585","GNMX","BK4535","HELX","LU0320765992.SGD","GDOC","PTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136746995","title":"Twinstrand:特拉華州法院於8月21日裁定公司及華盛頓大學在針對Guardant Health的專利侵權訴訟中勝訴","url":"https://stock-news.laohu8.com/highlight/detail?id=1136746995","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136746995?lang=zh_tw&edition=fundamental","pubTime":"2026-08-24 19:00","pubTimestamp":1787569211,"startTime":"0","endTime":"0","summary":"Twinstrand宣布,特拉华州法院已于8月21日作出判决,支持公司及华盛顿大学的立场,认定其在针对Guardant Health提起的专利侵权诉讼中占据优势。这一裁决标志着这场备受关注的法律纠纷取得了阶段性胜利。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","GDOC","BK4196","FFOX","GNMX","BK4585","HELX","LFSC","LU0320765992.SGD","LU0889565916.HKD","PTH","GNOM","GH","BK4535","BK4551","BK4588","EKG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660421558","title":"第3次更新-足球——謝菲爾德聯隊前所有者獲准申請清算當初收購該俱樂部的那家公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2660421558","media":"路透中文","labels":["policyRegulatory","merge","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660421558?lang=zh_tw&edition=fundamental","pubTime":"2026-08-19 22:49","pubTimestamp":1787150961,"startTime":"0","endTime":"0","summary":"第3次更新-足球——谢菲尔德联队前所有者获准申请清算当初收购该俱乐部的那家公司在第4至5段中补充了谢菲尔德联队的声明路透伦敦8月19日-谢菲尔德联队前所有者周三获准申请,将清算该公司——该公司在2024年收购了这支英冠球队。谢菲尔德联队表示,高等法院的裁决对俱乐部而言并非问题。但今年6月,谢菲尔德联队表示1919 Partners LLC是该俱乐部的母公司,对此,United World本周表示,此举“似乎是试图逃避向CSBL的债权人付款”。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260819:nL4S44G1AH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory,merge,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","GNMX","PTH","GNOM","GH","EKG","GDOC","LU0320765992.SGD","BK4196","HELX","FFOX","LFSC","LU0109394709.USD","BK4535","LU0889565916.HKD","BK4551"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659504119","title":"中國銀河證券:實驗動物為創新藥研發剛需 小鼠+猴雙主線高景氣","url":"https://stock-news.laohu8.com/highlight/detail?id=2659504119","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659504119?lang=zh_tw&edition=fundamental","pubTime":"2026-08-14 15:07","pubTimestamp":1786691225,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,中国银河证券发布研报称,实验动物为创新药研发刚需,行业壁垒深厚,两大细分赛道具备中长期成长逻辑:人源化小鼠赛道成长确定性更强、周期波动平缓;实验猴赛道供给约束强,短期价格上行带来显著业绩弹性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1479960.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["SBIO","GDOC","WRND","GSKH","BIOY","BK1564","LFSC","601881","APXH","06881","XLVI","IBB","BK4585","161027","BK4588","BBP","BK1147","BK0188","BK0276","PBE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659138517","title":"美銀證券:中國CXO行業受惠生物科技融資強勁 上調藥明康德等目標價","url":"https://stock-news.laohu8.com/highlight/detail?id=2659138517","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659138517?lang=zh_tw&edition=fundamental","pubTime":"2026-08-13 12:41","pubTimestamp":1786596060,"startTime":"0","endTime":"0","summary":"模拟交易客户端美银证券发布研报称,受惠上半年全球及中国生物科技一级市场融资表现强劲,加上创新药对外授权交易持续活跃,预期研发活动将进一步加快,中国CRO/CDMO企业可望受惠。该行上调药明康德H股目标价由204.3港元至242港元,药明康德A股目标价由177.8元人民币至210.5元人民币,维持“买入”评级,因其增长能见度清晰。该行并上调药明康德2029至2035年收入估算介乎3%至7%,经调整纯利预测亦上调介乎3%至7%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/hkgg/2026-08-13/doc-inincxku3329313.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LFSC","IBRN","02359","PSIL","XBIX","WX","IDNA","APXH","BMED","MEDI","161027","SURI","FHLC","PSCH","603259","BBC","CXO","SMCO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658903675","title":"百花醫藥股價嚴重異常波動:主營小分子化學仿製藥CRO業務 不涉及創新藥研發","url":"https://stock-news.laohu8.com/highlight/detail?id=2658903675","media":"央广财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658903675?lang=zh_tw&edition=fundamental","pubTime":"2026-08-12 21:27","pubTimestamp":1786541220,"startTime":"0","endTime":"0","summary":"8月12日,百花医药(维权)(600721.SH)发布公告称,公司股票连续10个交易日内日收盘价格涨幅偏离值累计超过100%,根据上交所的有关规定,属于股票交易严重异常波动情形。公司是以小分子化学仿制药研发为主的CRO企业,不涉及创新药研发。公司2026年第一季度实现营业收入6718.29万元,同比下降30.68%,归属于上市公司股东的净利润664.27万元,同比下降67.94%。目前公司主营业务未发生重大变化,市场环境、行业政策没有发生重大调整,股价短期内连续上涨,涨幅与公司经营情况严重偏离。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-08-12/doc-ininamih5206238.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BBP","GDOC","LFSC","600721","BK0102","BK0216","GSKH","PBE","XLVI","BK4585","IBB","SBIO","BIOY","WRND","APXH","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658692990","title":"百花醫藥(600721.SH):不涉及創新藥研發","url":"https://stock-news.laohu8.com/highlight/detail?id=2658692990","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658692990?lang=zh_tw&edition=fundamental","pubTime":"2026-08-11 20:03","pubTimestamp":1786449780,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["PBE","IBB","LFSC","XLVI","BK4585","BBP","GDOC","WRND","BIOY","BK4588","SBIO","APXH","GSKH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658667990","title":"百花醫藥(600721.SH):不涉及創新藥研發","url":"https://stock-news.laohu8.com/highlight/detail?id=2658667990","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658667990?lang=zh_tw&edition=fundamental","pubTime":"2026-08-11 20:03","pubTimestamp":1786449780,"startTime":"0","endTime":"0","summary":"智通财经APP讯,百花医药(600721.SH)发布股票交易风险提示公告称,公司是以小分子化学仿制药研发为主的CRO企业,主营业务是为客户提供小分子化仿药为主的药物研发注册“一站式”全流程服务,主要研发项目多来自于客户委托加部分的公司自主立项,不涉及创新药研发。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1478640.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IBB","BK4588","600721","GDOC","GSKH","WRND","APXH","XLVI","BK4585","LFSC","PBE","BIOY","BK0102","BBP","SBIO","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658962968","title":"東方證券:AI重構創新藥研發底座 國內相關產業鏈公司亦有望受益","url":"https://stock-news.laohu8.com/highlight/detail?id=2658962968","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658962968?lang=zh_tw&edition=fundamental","pubTime":"2026-08-11 14:06","pubTimestamp":1786428403,"startTime":"0","endTime":"0","summary":"东方证券主要观点如下:技术颠覆成本,AI重构制药“快与省”是中国创新药崛起的底层逻辑,根基是人才红利和成本优势。专家与AI协同,将真正提升新药研发的成功率并缩短周期。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1478422.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0012","BK0276","QTOC","AIPO","PBE","ARTY","BIOY","BK4588","VTHR","LFSC","XLVI","BK4585","IBB","WRND","BBP","SBIO","CHAT","APXH","BK1147","GSKH","600958","AGIX","BK1564","BK0183","GDOC","BK0188","03958","BK0028"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":51,"code":"91000000","status":"200"}]}}